Clinical trial updates

Ferroportin inhibitors



Update: 05 November 2020

No update available.


Update: 25 August 2020

  • Data presented at the EHA Congress in June indicate that treatment with the oral ferroportin inhibitor VIT-2763 alone or in combination with DFX significantly increases haemoglobin.



Update: 31 May 2020

  • A phase 2 multiple dose, multicentre (USA & GR), double-blind, placebo-controlled parallel group study (VITHAL) in 36 adult and adolescent patients with NTDT is expected to start in June 2020.
  • The study includes a 12-week treatment period and a safety follow-up period of 4 weeks.



Update: 31 March 2020

No update available.


Update: 31 January 2020

No update available.


Update: 25 November 2019

No update available.


Update: 27 September 2019

No update available


Update: 30 July 2019

Results announced during 24th Annual Congress of the European Hematology Association show that treatment with single and multiple oral doses of VIT-2763 were well tolerated in healthy subjects, decreasing the iron levels in circulation.

A proof of concept study in patients with β-thalassaemia is supported by these results.



Update: 30 May 2019

No update available.


 Update: 01 February 2019

A randomized, controlled, multi-centred phase 2 proof-of-concept trial will begin in the second half of 2019 to assess the effectiveness of the oral ferroportin inhibitor (VIT-2763) on iron overload in β-thalassaemia patients.

Phase 1 trials have shown positive results with a consistent lower serum iron for up to 24 hours post-dose. The results are dose-dependent.

Treatment with VIT-2763 can improve iron metabolism and the production of RBCs.



Check Also
Back to top button